SG10201710013RA - Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof - Google Patents

Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof

Info

Publication number
SG10201710013RA
SG10201710013RA SG10201710013RA SG10201710013RA SG10201710013RA SG 10201710013R A SG10201710013R A SG 10201710013RA SG 10201710013R A SG10201710013R A SG 10201710013RA SG 10201710013R A SG10201710013R A SG 10201710013RA SG 10201710013R A SG10201710013R A SG 10201710013RA
Authority
SG
Singapore
Prior art keywords
pai
antibodies
plasminogen activator
activator inhibitor
inhibitor
Prior art date
Application number
SG10201710013RA
Other languages
English (en)
Inventor
Alla Pritsker
Patrick Grailhe
Alexey Rak
Magali Mathieu
Christopher Ryan Morgan
Nicolas Baurin
Bruno Poirier
Cyril Daveu
Francis Duffieux
Han Li
Dorothea KOMINOS
Philip Janiak
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG10201710013RA publication Critical patent/SG10201710013RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
SG10201710013RA 2013-08-13 2014-08-13 Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof SG10201710013RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361865451P 2013-08-13 2013-08-13
EP14305757 2014-05-22

Publications (1)

Publication Number Publication Date
SG10201710013RA true SG10201710013RA (en) 2018-01-30

Family

ID=56194112

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201710013RA SG10201710013RA (en) 2013-08-13 2014-08-13 Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof

Country Status (17)

Country Link
US (4) US9845363B2 (cg-RX-API-DMAC7.html)
JP (5) JP6696899B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160035077A (cg-RX-API-DMAC7.html)
CN (2) CN112142845A (cg-RX-API-DMAC7.html)
BR (1) BR112016002753A2 (cg-RX-API-DMAC7.html)
CL (1) CL2016000324A1 (cg-RX-API-DMAC7.html)
CR (2) CR20190319A (cg-RX-API-DMAC7.html)
DO (1) DOP2016000042A (cg-RX-API-DMAC7.html)
EA (1) EA033403B1 (cg-RX-API-DMAC7.html)
ES (1) ES2770507T3 (cg-RX-API-DMAC7.html)
HK (1) HK1221725A1 (cg-RX-API-DMAC7.html)
MX (2) MX2016001851A (cg-RX-API-DMAC7.html)
PE (1) PE20160244A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016500239A1 (cg-RX-API-DMAC7.html)
SG (1) SG10201710013RA (cg-RX-API-DMAC7.html)
TN (1) TN2016000048A1 (cg-RX-API-DMAC7.html)
UA (1) UA118267C2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA118267C2 (uk) * 2013-08-13 2018-12-26 Санофі Антитіло до інгібітора активатора плазміногену 1 (раі-1) та його застосування
WO2017101870A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法
CN108778320A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗心血管病的新方法
DK3395354T3 (da) 2015-12-18 2024-06-03 Talengen Int Ltd Plasminogen til anvendelse i behandling af diabetisk nefropati
ES2982294T3 (es) 2015-12-18 2024-10-15 Talengen Int Ltd Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus
WO2018107690A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法
CN108210910A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗系统性硬化症的药物及其用途
CN110114079A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗肥胖症的方法和药物
US11311607B2 (en) * 2016-12-15 2022-04-26 Talengen International Limited Method for making glucagon and insulin restore normal balance
CN108210900A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肥胖症的药物及其用途
WO2018107697A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肺纤维化的方法
JP7182793B2 (ja) * 2016-12-15 2022-12-05 タレンゲン インターナショナル リミテッド 病理学的腎組織損傷を予防及び治療するための方法
JP7335609B2 (ja) 2017-06-19 2023-08-30 タレンゲン インターナショナル リミテッド Ｇｌｐ－１／ｇｌｐ－１ｒを調節制御する方法および薬剤
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
PE20200486A1 (es) * 2017-08-03 2020-03-03 Alector Llc Anticuerpos anti-cd33 y metodos para utilizarlos
CA3176021A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use
US20220340665A1 (en) 2019-09-30 2022-10-27 Renascience Inc. Inhibitor against expression of immune checkpoint molecule
KR20220093327A (ko) * 2019-10-28 2022-07-05 모나쉬 유니버시티 플라스미노겐에 결합하기 위한 항체
TWI884192B (zh) * 2019-12-05 2025-05-21 美商西健公司 抗αＶβ６抗體及抗體-藥物結合物
CN115605219A (zh) * 2020-02-11 2023-01-13 泰伦基国际有限公司（Hk） 一种治疗病毒性肺炎的方法和药物
CN111072780B (zh) * 2020-03-24 2020-06-23 深圳汉盛汇融再生医学科技有限公司 白血病干细胞抑制剂及其在治疗慢性粒细胞白血病中的应用
AR122480A1 (es) * 2020-05-21 2022-09-14 Cadila Healthcare Ltd VARIANTE DE LA Fc Y PREPARACIÓN DE LA MISMA
CN114605550B (zh) * 2020-12-08 2023-09-22 东莞市朋志生物科技有限公司 抗ca19-9的抗体、其应用和检测ca19-9的试剂盒
CN114686441B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 一种能分泌tPAI-C单克隆抗体的杂交瘤细胞株及其应用
CN114686442B (zh) * 2020-12-31 2023-11-07 广州万孚生物技术股份有限公司 一种杂交瘤细胞株及其应用
CN115873120B (zh) * 2022-09-08 2025-10-21 厦门英博迈生物科技有限公司 一种纤溶酶α2纤溶酶抑制物复合物抗体及应用
WO2025032553A1 (en) * 2023-08-10 2025-02-13 Cochlear Limited Methods of treating inner ear fibrosis

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5422245A (en) * 1985-07-12 1995-06-06 Fonden Til Fremme Af Eksperimental Cancerforskning Plasminogen activator inhibitor monoclonal antibodies, hybridomas, monoclonal antibody production and use of the antibodies for assay of the inhibitors
DK319685A (da) * 1985-07-12 1987-01-13 Fonden Til Fremme Af Eksperime Monoklonale antistoffer, fremgangsmaade til frembringelse af antistofferne, hybridomaceller, der producerer antistofferne, og anvendelse af antistofferne
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JP2750732B2 (ja) * 1988-04-04 1998-05-13 帝人株式会社 ヒトプラスミノーゲンアクティベーターインヒビター・１−ヒト組織プラスミノーゲンアクティベーター複合体の免疫学的測定方法
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0521985B1 (en) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
JPH1014592A (ja) * 1996-07-04 1998-01-20 Tanabe Seiyaku Co Ltd ラットｐａｉ−１に対するモノクローナル抗体
ES2300113T3 (es) 1996-08-02 2008-06-01 Bristol-Myers Squibb Company Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo.
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
AU2001229441A1 (en) * 2000-01-14 2001-07-24 Tanox, Inc. Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease
WO2002034776A2 (en) 2000-10-26 2002-05-02 K.U.Leuven Research And Development Epitopes of pai-1
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP1485709A4 (en) * 2002-02-19 2005-09-21 Univ Vanderbilt THERAPIES OF PAI-1 INHIBITORS AND NON-HUMAN TRANSGENIC ANIMALS FOR THE SYSTEMATIC RESEARCH OF PAI-1 INHIBITING CANDIDATES
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
CN1668312A (zh) * 2002-05-13 2005-09-14 洛杉矶儿童医院 疤痕疙瘩和其它的皮肤或内部的创伤或损伤中异常疤痕形成的处理和抑制
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
EP2502935B1 (en) 2003-08-22 2017-03-29 Biogen MA Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
JP2008505174A (ja) 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US20090202524A1 (en) 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
PT2195023T (pt) 2007-08-29 2018-06-08 Sanofi Sa Anticorpos anti-cxcr5 humanizados, seus derivados e suas utilizações
EP2198055A4 (en) * 2007-09-07 2012-04-18 Cisthera Inc HUMANIZED PAI-1 ANTIBODIES
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US8410251B2 (en) * 2008-06-20 2013-04-02 National University Corporation Okayama University Antibody against calcified globule and use of the same
US20100254979A1 (en) * 2009-03-06 2010-10-07 Cisthera, Incorporated Humanized PAI-1 Antibodies and Uses Thereof
US20120114652A1 (en) * 2010-05-03 2012-05-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
UA118267C2 (uk) * 2013-08-13 2018-12-26 Санофі Антитіло до інгібітора активатора плазміногену 1 (раі-1) та його застосування

Also Published As

Publication number Publication date
CN105705520B (zh) 2020-09-25
MX2016001851A (es) 2016-05-16
JP6907380B2 (ja) 2021-07-21
MX2019008803A (es) 2019-09-16
US20180155444A1 (en) 2018-06-07
BR112016002753A2 (pt) 2017-11-21
JP2021155440A (ja) 2021-10-07
HK1221725A1 (zh) 2017-06-09
JP7764565B2 (ja) 2025-11-05
EA033403B1 (ru) 2019-10-31
CR20160117A (es) 2016-05-20
KR20160035077A (ko) 2016-03-30
JP2016529255A (ja) 2016-09-23
JP2023055852A (ja) 2023-04-18
UA118267C2 (uk) 2018-12-26
DOP2016000042A (es) 2016-04-04
JP6696899B2 (ja) 2020-05-20
PH12016500239A1 (en) 2016-05-16
JP2020125333A (ja) 2020-08-20
ES2770507T3 (es) 2020-07-01
US20190359729A1 (en) 2019-11-28
CL2016000324A1 (es) 2016-10-21
TN2016000048A1 (en) 2017-07-05
US20160200831A1 (en) 2016-07-14
CR20190319A (es) 2019-08-29
PE20160244A1 (es) 2016-05-10
JP7223069B2 (ja) 2023-02-15
JP7568756B2 (ja) 2024-10-16
JP2025011161A (ja) 2025-01-23
EA201690377A1 (ru) 2016-06-30
US20230015181A1 (en) 2023-01-19
CN105705520A (zh) 2016-06-22
CN112142845A (zh) 2020-12-29
US9845363B2 (en) 2017-12-19

Similar Documents

Publication Publication Date Title
SG10201710013RA (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
IL244018A0 (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
IL280155A (en) Anti- SIGLEC-8 antibodies and methods of using them
IL261743B (en) and their uses 33–il antibodies against
IL261547B (en) Antibodies against pesidine and their uses
IL245040B (en) Antibodies against pdgfr-beta and their uses
IL243974A0 (en) Antibodies against -prlr and uses
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
ZA201603308B (en) Novel anti-claudin antibodies and methods of use
IL245946A0 (en) Anti-dpep3 antibodies and methods of use
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
IL244590A0 (en) Anti-epcam antibodies and methods of use
SG11201602760YA (en) Monoclonal olfml-3 antibodies and uses thereof